Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer.

George W Sledge¹, Joanne Xiu², Suzanne Fuqua³, Jennifer R Ribeiro², Heather McArthur⁴, Matthew J Oberley², Milan Radovich⁵, David Spetzler⁶, Virginia Kaklamani⁷

¹Caris Life Sciences (United States) Palo Alto, CA United States.

²Caris Life Sciences (United States) Phoenix, AZ United States.

³Baylor College of Medicine Houston, TX United States.

⁴Cedars-Sinai Medical Center Dallas, TX United States.

⁵Caris Life Sciences (United States) Irving, TX United States.

⁶Caris Life Sciences (United States) Tempe, Az United States.

⁷The University of Texas at San Antonio Health Science Center San Antonio, Texas United States.

PubMed DOI

Abstract

BACKGROUND: ESR1 mutations are a well-established mechanism of endocrine therapy resistance in estrogen receptor (ER)-positive metastatic breast cancer and are a biomarker for treatment benefit from oral selective estrogen receptor degraders (SERDs) such as elacestrant. However, variant-specific and context-dependent effects on therapy response remain poorly understood. METHODS: Breast tumors car…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.